# AMP-AD Data Coordination Center

> **NIH NIH U24** · SAGE BIONETWORKS · 2021 · $2,437,076

## Abstract

Project Summary/Abstract
Alzheimer’s Disease (AD) is a debilitating neurodegenerative disease affecting more than 5 million Americans.
Despite significant investment in drug discovery and development, no therapeutic options yet exist that can
prevent, slow, or cure AD. The Accelerating Medicines Partnership in Alzheimer’s Disease Target Discovery
and Preclinical Validation project (AMP-AD) was designed to help address this problem by identifying
candidate targets through evaluation of AD-induced changes in human molecular state on a systems level. The
program uses an open science paradigm to support early, iterative integration of resources and evaluation of
findings across multiple independent teams. This approach was designed to improve observations through
integration of multiple data sources, to increase confidence in outcomes through transparency, reproducibility,
and benchmarking of methods and to accelerate evaluation of nominated AD targets by aggregating evidence
and expertise across the field. Cross-consortium activities are supported by the Data Coordination Center
(DCC) led by Sage Bionetworks. Functions include resource sharing, performance of cross-team analytical
projects, and coordinated evaluation across the program of research outcomes. The overarching goal of AMP-
AD Data Coordinating Center is to advance the AMP-AD research program through open science practices for
coordinated and integrated evaluation of AD targets. As the AMP-AD community expands in terms of people,
data, and research projects, several extensions to the existing DCC services are necessary to fully support the
program. These include: (a) improved mechanisms to identify resources across the expanding spectrum of
projects, (b) support for biologists without informatics expertise to interpret and use AD systems biology
resources, (c) mechanisms to integrate external expertise and/or resources where they are needed to advance
program goals, and (d) targeted analyses that serve to bridge analytical gaps across individual projects. By
combining existing services with these advancements, the DCC will work to: 1. Distribute AMP-AD systems
biology assets through the AMP-AD Knowledge Portal. 2. Integrate research efforts across AMP-AD projects
through cross-team analyses. 3. Expand the broader impact of AMP-AD through community outreach. The
proposed work is designed to maximize the vast resources and biological insights within AMP-AD and to
accelerate characterization and validation of AMP-AD targets through the open dissemination and evaluation
of a set of high-confidence therapeutic targets.

## Key facts

- **NIH application ID:** 10242012
- **Project number:** 5U24AG061340-04
- **Recipient organization:** SAGE BIONETWORKS
- **Principal Investigator:** ANNA K GREENWOOD
- **Activity code:** U24 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $2,437,076
- **Award type:** 5
- **Project period:** 2018-09-30 → 2023-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10242012

## Citation

> US National Institutes of Health, RePORTER application 10242012, AMP-AD Data Coordination Center (5U24AG061340-04). Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/grant/nih/10242012. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*